These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35811461)

  • 1. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies.
    Ollila TA; Masel RH; Reagan JL; Lu S; Rogers RD; Paiva KJ; Taher R; Burguera-Couce E; Zayac AS; Yakirevich I; Niroula R; Barth P; Olszewski AJ
    Cancer; 2022 Sep; 128(18):3319-3329. PubMed ID: 35811461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders.
    Ammitzbøll C; Kragh Thomsen M; Bøgh Andersen J; Jensen JMB; From Hermansen ML; Dahl Johannsen A; Larsen ML; Mistegaard CE; Mikkelsen S; Szabados F; Vils SR; Erikstrup C; Hauge EM; Troldborg A
    Rheumatology (Oxford); 2023 Jul; 62(7):2544-2549. PubMed ID: 36445008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario.
    Krekeler C; Reitnauer L; Bacher U; Khandanpour C; Steger L; Boeckel GR; Klosner J; Tepasse PR; Kemper M; Hennies MT; Mesters R; Stelljes M; Schmitz N; Kerkhoff A; Schliemann C; Mikesch JH; Schmidt N; Lenz G; Bleckmann A; Shumilov E
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms.
    Kobayashi M; Mori A; Onozawa M; Tsukamoto S; Senjo H; Ishio T; Yokoyama E; Kanaya M; Izumiyama K; Saito M; Muraki H; Morioka M; Teshima T; Kondo T
    Ann Hematol; 2023 Apr; 102(4):819-827. PubMed ID: 36862167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.
    Marchesi F; Salmanton-García J; Buquicchio C; Itri F; Besson C; Dávila-Valls J; Martín-Pérez S; Fianchi L; Rahimli L; Tarantini G; Grifoni FI; Sciume M; Labrador J; Cordoba R; López-García A; Fracchiolla NS; Farina F; Ammatuna E; Cingolani A; García-Bordallo D; Gräfe SK; Bilgin YM; Dargenio M; González-López TJ; Guidetti A; Lahmer T; Lavilla-Rubira E; Méndez GA; Prezioso L; Schönlein M; Van Doesum J; Wolf D; Hersby DS; Magyari F; Van Praet J; Petzer V; Tascini C; Falces-Romero I; Glenthøj A; Cornely OA; Pagano L
    J Hematol Oncol; 2023 Apr; 16(1):32. PubMed ID: 37005697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
    Guven DC; Sahin TK; Akın S; Uckun FM
    Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies.
    Chung DJ; Shah GL; Devlin SM; Ramanathan LV; Doddi S; Pessin MS; Hoover E; Marcello LT; Young JC; Boutemine SR; Serrano E; Sharan S; Momotaj S; Margetich L; Bravo CD; Papanicolaou GA; Kamboj M; Mato AR; Roeker LE; Hultcrantz M; Mailankody S; Lesokhin AM; Vardhana SA; Knorr DA
    Blood Cancer Discov; 2021 Nov; 2(6):568-576. PubMed ID: 34778797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.
    Uaprasert N; Pitakkitnukun P; Tangcheewinsirikul N; Chiasakul T; Rojnuckarin P
    Blood Cancer J; 2022 Dec; 12(12):173. PubMed ID: 36550105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies.
    Huang CT; Lee CP; Chen TY; Liu YC; Cho SF; Du JS; Yu ML; Huang CF; Wang SF; Hsiao HH
    J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies.
    Owen C; Robinson S; Christofides A; Sehn LH
    Curr Oncol; 2022 May; 29(6):3940-3949. PubMed ID: 35735424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?
    Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
    Clin Exp Immunol; 2022 May; 207(3):263-271. PubMed ID: 35553629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies.
    Reimann P; Petzer V; Mündlein A; Hartmann B; Severgnini L; Winkler A; Lang T; Huynh M; Gasser K; Rüger J; Atzl M; Mink S; Fraunberger P; Schmidt S; Steiner N; Griesmacher A; Gunsilius E; Nachbaur D; Willenbacher W; Wolf D; Winder T; Benda MA
    Ann Hematol; 2024 Jun; 103(6):2123-2131. PubMed ID: 38436671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies.
    Mori A; Onozawa M; Kobayashi M; Tsukamoto S; Senjo H; Ishio T; Yokoyama E; Kanaya M; Izumiyama K; Saito M; Muraki H; Morioka M; Teshima T; Kondo T
    Cancer Med; 2023 Aug; 12(16):16881-16888. PubMed ID: 37409608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
    Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
    Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study.
    Demel I; Skopal D; Šafránková E; Rozsívalová P; Jindra P; Šrámek J; Turková A; Vydra J; Labská K; Vedrová J; Čerňan M; Szotkowski T; Móciková H; Hynková L; Šušol O; Kováčová I; Belada D; Hájek R
    Ann Hematol; 2024 Mar; 103(3):981-992. PubMed ID: 38092996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of Booster Vaccination in Children with Primary Vaccine Failure after Initial Varicella Vaccination].
    Ozakiv T; Nishimura N; Gotoh K; Funahashi K; Yoshii H; Okuno Y
    Kansenshogaku Zasshi; 2016 May; 90(3):291-6. PubMed ID: 27529963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
    Bonelli M; Mrak D; Tobudic S; Sieghart D; Koblischke M; Mandl P; Kornek B; Simader E; Radner H; Perkmann T; Haslacher H; Mayer M; Hofer P; Redlich K; Husar-Memmer E; Fritsch-Stork R; Thalhammer R; Stiasny K; Winkler S; Smolen JS; Aberle JH; Zeitlinger M; Heinz LX; Aletaha D
    Ann Rheum Dis; 2022 May; 81(5):687-694. PubMed ID: 35027397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy.
    Cohen D; Hazut Krauthammer S; Cohen YC; Perry C; Avivi I; Herishanu Y; Even-Sapir E
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3540-3549. PubMed ID: 33966088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
    Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
    ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.
    Corti C; Antonarelli G; Scotté F; Spano JP; Barrière J; Michot JM; André F; Curigliano G
    Ann Oncol; 2022 Feb; 33(2):158-168. PubMed ID: 34718117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.